GO:0032553 ribonucleotide binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032553 (ribonucleotide binding) is a molecular function describing the binding of any ribonucleotide, defined as a ribonucleoside esterified with phosphate or oligophosphate at any ribose hydroxyl group.
• Ribonucleotide binding is central to nucleotide metabolism, nucleic acid synthesis, and allosteric regulation of enzymes such as ribonucleotide reductase [2,4,8].
• The AMP-activated protein kinase (AMPK) binds AMP and ATP, which are ribonucleotides, to sense cellular energy status [1,5].
• Ribonucleotide binding motifs are ancient and can be traced to early Earth through ligand mimicry.
• Dysregulated ribonucleotide binding contributes to cancer, metabolic disorders, and cartilage pathology [3,1].
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise interrogation of ribonucleotide-binding proteins.
Description
Ribonucleotide binding (GO:0032553) is a fundamental molecular function that underpins numerous biological processes, from DNA synthesis to cellular energy sensing. Ribonucleotides such as ATP, GTP, CTP, and UTP serve as substrates for polymerases, as allosteric effectors, and as signaling molecules. The binding of these compounds to proteins is essential for their catalytic and regulatory roles [2,4,8]. Understanding ribonucleotide binding is critical for researchers studying nucleotide metabolism, signal transduction, and disease mechanisms. For example, ribonucleotide reductase, which catalyzes the reduction of ribonucleotides to deoxyribonucleotides, requires precise binding of allosteric effectors to control substrate specificity and activity [4,8]. Similarly, AMPK binds AMP and ATP to monitor energy charge and regulate metabolism [1,5]. The evolutionary origins of ribonucleotide recognition motifs have been explored, suggesting that these binding interactions date back to early life. This article provides a comprehensive overview of the ontology, mechanisms, key genes, and research methods associated with ribonucleotide binding, with a focus on how CRISPR-based models can accelerate discovery.
ribonucleotide binding At A Glance
| GO ID | GO:0032553 |
|---|---|
| GO term | ribonucleotide binding |
| Ontology | molecular_function |
| Synonym | none |
| Major function | Binding to ribonucleotides such as ATP, GTP, CTP, UTP, and their derivatives |
| Definition source | QuickGO |
| Related terms | nucleotide binding, ATP binding, RNA binding |
| Examples of proteins | Ribonucleotide reductase, AMPK, PurK, and many kinases |
What Is GO:0032553?
According to the Gene Ontology, GO:0032553 (ribonucleotide binding) is defined as the binding to a ribonucleotide, any compound consisting of a ribonucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose moiety. In simpler terms, it is the molecular function of selectively interacting with ribonucleotides, which are the building blocks of RNA and key energy carriers like ATP.
Why Is ribonucleotide binding Important in Cell Biology?
Ribonucleotide binding is essential for life because ribonucleotides are not only precursors for RNA synthesis but also universal energy currency and signaling molecules. Proteins that bind ribonucleotides regulate metabolism, cell growth, and stress responses. Dysregulation of these interactions is linked to cancer, metabolic diseases, and developmental disorders [1,2,3,5]. Therefore, studying ribonucleotide binding provides insights into basic biology and offers therapeutic targets.
• Ribonucleotide binding controls the activity of ribonucleotide reductase, a key enzyme for DNA synthesis and repair [2,4,8].
• AMPK binds AMP/ATP to sense energy status and regulate metabolism, with implications for diabetes and cancer [1,5].
• Ribonucleotide binding motifs are evolutionarily ancient, informing origins-of-life research.
• Cartilage-derived ribonucleotide binding activity may be relevant to joint diseases.
• PurK, a bacterial enzyme, binds ribonucleotide intermediates in purine biosynthesis, a target for antibiotics.
• Altered ribonucleotide binding can lead to chemotherapy resistance and metabolic reprogramming in cancer.
• Ribonucleotide binding is critical for antiviral and anticancer drug design.
• Understanding these interactions aids in developing allosteric modulators.
• CRISPR screens can identify genes involved in ribonucleotide binding pathways.
• Ribonucleotide binding is a common feature of many kinases and GTPases.
Molecular Mechanism of ribonucleotide binding
Substrate Recognition and Binding Pocket
In simple terms: Proteins have specific pockets that fit ribonucleotides like a lock and key.
Ribonucleotide-binding proteins typically contain conserved motifs, such as the P-loop (Walker A motif) or Rossmann fold, that coordinate the phosphate groups and ribose moiety. For example, ribonucleotide reductase R1 binds allosteric effectors through a specificity site, where binding of ATP or dATP modulates substrate preference. The binding pocket recognizes the ribose 2'-hydroxyl group, distinguishing ribonucleotides from deoxyribonucleotides.
Allosteric Regulation by Ribonucleotides
In simple terms: Binding of a ribonucleotide at one site can change the protein's shape and activity elsewhere.
Many enzymes are allosterically regulated by ribonucleotides. Ribonucleotide reductase is a classic example: binding of ATP to the activity site stimulates overall activity, while dATP inhibits it [4,8]. AMPK binds AMP and ATP at its gamma subunit, leading to conformational changes that control kinase activity [1,5]. This allostery is crucial for metabolic homeostasis.
Catalytic Mechanisms Involving Ribonucleotide Binding
In simple terms: Some proteins use bound ribonucleotides as cofactors to perform chemical reactions.
Ribonucleotide reductases use a radical mechanism to reduce ribonucleotides to deoxyribonucleotides, requiring binding of the substrate and allosteric effectors [2,4]. PurK, involved in purine biosynthesis, binds a ribonucleotide intermediate and bicarbonate to catalyze carboxylation. These catalytic roles highlight the chemical versatility of ribonucleotide binding.
Evolutionary Conservation of Ribonucleotide Binding
In simple terms: The ability to bind ribonucleotides is very old and found in many forms of life.
Ribonucleotide recognition motifs are thought to have originated early in evolution, possibly through ligand mimicry. The conservation of these motifs across bacteria, plants, and animals underscores their fundamental importance. Studies on Escherichia coli ribonucleotide reductase have provided insights into substrate binding that apply to higher organisms.
Key Genes Involved in GO:0032553 ribonucleotide binding
The following genes and proteins are representative examples of ribonucleotide-binding proteins, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| RRM1 | Ribonucleotide reductase subunit 1; binds allosteric effectors and substrates | Target for cancer therapy; allosteric regulation studies [4,8] |
| RRM2 | Ribonucleotide reductase subunit 2; contains catalytic radical | DNA synthesis and repair; chemotherapy resistance |
| PRKAA1 | AMPK catalytic alpha-1 subunit; binds AMP/ATP | Metabolic regulation; diabetes and cancer [1,5] |
| PRKAA2 | AMPK catalytic alpha-2 subunit; binds AMP/ATP | Energy sensing; metabolic diseases [1,5] |
| PRKAB1 | AMPK beta-1 subunit; binds glycogen and nucleotides | Allosteric regulation of AMPK |
| PRKAG1 | AMPK gamma-1 subunit; binds AMP/ATP | Nucleotide binding and energy sensing [1,5] |
| PURK | Phosphoribosylaminoimidazole carboxylase; binds ribonucleotide intermediate | Bacterial purine biosynthesis; antibiotic target |
| AKT1 | Kinase that binds ATP | Cell survival signaling; cancer |
| MAPK1 | Kinase that binds ATP | Proliferation signaling; cancer |
| EGFR | Receptor tyrosine kinase that binds ATP | Cancer therapy target |
| HSP90AA1 | Chaperone that binds ATP | Protein folding; cancer |
| GAPDH | Glycolytic enzyme that binds NAD+ (a ribonucleotide derivative) | Metabolism; moonlighting functions |
| CTPS1 | CTP synthase; binds UTP and ATP | Pyrimidine synthesis; cancer |
| IMPDH1 | Inosine monophosphate dehydrogenase; binds IMP (ribonucleotide) | Guanine nucleotide synthesis; immunosuppression |
| GMPS | GMP synthase; binds ATP and xanthosine monophosphate | Purine synthesis; cancer |
| NME1 | Nucleoside diphosphate kinase; binds ATP | Metastasis suppressor; nucleotide metabolism |
| RAC1 | GTPase that binds GTP | Cytoskeleton dynamics; cancer |
| KRAS | GTPase that binds GTP | Oncogene; cancer therapy |
How Is ribonucleotide binding Regulated?
Ribonucleotide binding is regulated at multiple levels. Allosteric effectors such as ATP, dATP, and dGTP modulate the activity of ribonucleotide reductase, ensuring balanced deoxyribonucleotide pools [4,8]. AMPK activity is controlled by the AMP/ATP ratio, which reflects cellular energy status [1,5]. Additionally, post-translational modifications and protein-protein interactions can influence nucleotide binding affinity. For instance, the binding of substrates to E. coli ribonucleotide reductase is affected by the redox state of active-site cysteines. These regulatory mechanisms are critical for maintaining cellular homeostasis.
ribonucleotide binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| RRM1 | Cancer (lung, pancreatic) | Knockout in cancer cell lines; point mutations in allosteric sites |
| RRM2 | Cancer, chemotherapy resistance | Overexpression and knockdown models |
| PRKAA1 | Type 2 diabetes, metabolic syndrome | Knockout mice; point mutations in AMP-binding domain |
| PURK | Bacterial infections (Bacillus anthracis) | Knockout in bacterial strains; enzyme assays |
| CTPS1 | Cancer, immunodeficiency | Knockout in cell lines; overexpression |
Cancer
Dysregulated ribonucleotide binding is a hallmark of cancer. Overexpression of ribonucleotide reductase subunits (RRM1, RRM2) increases deoxyribonucleotide pools, supporting rapid DNA replication and tumor growth [2,4]. AMPK, which binds AMP/ATP, has context-dependent roles in cancer; its activation can inhibit proliferation but also promote survival under metabolic stress [1,5]. Targeting ribonucleotide-binding proteins is a therapeutic strategy, with inhibitors like gemcitabine and hydroxyurea.
Metabolic Disorders
AMPK is a key regulator of glucose and lipid metabolism. Mutations affecting its nucleotide-binding domains can lead to metabolic syndromes, including type 2 diabetes and obesity [1,5]. Metformin, a first-line antidiabetic drug, acts in part by activating AMPK through effects on AMP binding. Thus, ribonucleotide binding is directly linked to metabolic disease pathology.
Cartilage and Joint Diseases
A cartilage-derived ribonucleotide binding activity has been described, suggesting a role in joint biology. Although the specific protein remains to be identified, this activity may be relevant to osteoarthritis and rheumatoid arthritis. Further research could uncover new therapeutic targets.
From ribonucleotide binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of RRM1 affect deoxyribonucleotide pools? | Knockout cell lines (e.g., HCT116) with rescue |
| How do point mutations in AMPK gamma subunit alter AMP binding? | Point-mutation knock-in in HEK293 cells |
| Can overexpression of RRM2 drive chemoresistance? | Overexpression in cancer cell lines |
| What is the role of PurK in bacterial survival? | Knockout in Bacillus anthracis |
| Does tagging RRM1 with GFP affect its localization? | Knock-in of GFP tag at endogenous locus |
| Which genes are essential for ribonucleotide binding? | CRISPR library screening in haploid cells |
How to Study the ribonucleotide binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Isothermal titration calorimetry (ITC) | Binding affinity and thermodynamics | Characterizing allosteric effector binding to RRM1 |
| Surface plasmon resonance (SPR) | Real-time binding kinetics | Screening small molecule inhibitors |
| X-ray crystallography | 3D structure of protein-ligand complex | Visualizing nucleotide binding pocket |
| CRISPR knockout screening | Gene essentiality and fitness | Identifying genes required for ribonucleotide salvage |
| Metabolomics (LC-MS) | Intracellular ribonucleotide levels | Assessing metabolic impact of AMPK mutations |
| RNA-seq | Transcriptional changes | Evaluating cellular response to nucleotide stress |
| Proteomics (AP-MS) | Protein-protein interactions | Finding novel ribonucleotide-binding proteins |
| Fluorescence polarization | Binding affinity in solution | High-throughput screening of nucleotide analogs |
Biochemical Binding Assays
Direct measurement of ribonucleotide binding can be achieved using isothermal titration calorimetry (ITC), surface plasmon resonance (SPR), or fluorescence polarization. These methods provide dissociation constants and stoichiometry. For example, binding of allosteric effectors to ribonucleotide reductase R1 was characterized using equilibrium dialysis and kinetic assays [4,8].
Structural Biology
X-ray crystallography and cryo-EM reveal atomic details of ribonucleotide binding pockets. The structure of E. coli ribonucleotide reductase with substrates and effectors elucidated the mechanism of allosteric regulation. Similarly, the bicarbonate binding site of PurK was resolved by crystallography.
Genetic Screens and CRISPR
CRISPR knockout screens can identify genes required for cell growth under conditions that demand ribonucleotide binding, such as nucleotide deprivation. Point mutations can be introduced to disrupt specific binding residues, and knock-in reporters can track binding dynamics in live cells.
Metabolomics and Flux Analysis
Mass spectrometry-based metabolomics quantifies ribonucleotide pools and isotope tracing reveals flux through pathways. These approaches are powerful for studying how perturbations in ribonucleotide-binding proteins affect metabolism [1,5].
How CRISPR Can Be Used to Study GO:0032553 ribonucleotide binding
Knockout
CRISPR knockout of genes encoding ribonucleotide-binding proteins, such as RRM1 or PRKAA1, can reveal their essentiality and downstream effects. For example, RRM1 knockout is lethal in most cell lines, but conditional knockouts allow studying nucleotide pool imbalances [2,4].
Point Mutation
Introducing point mutations in nucleotide-binding motifs (e.g., Walker A lysine to alanine) can abolish binding without affecting protein stability. This approach has been used to dissect AMPK's AMP-binding site [1,5].
Knock-in
Knock-in of tagged versions (e.g., GFP, HaloTag) of ribonucleotide-binding proteins enables live-cell imaging and proteomics. Knock-in of disease-associated mutations can model human disorders.
Overexpression
Overexpression of ribonucleotide-binding proteins, such as RRM2, can mimic cancer-associated upregulation and test drug resistance. Inducible systems allow temporal control.
How EDITGENE Supports ribonucleotide binding Research
Researchers studying ribonucleotide binding-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides comprehensive CRISPR-based services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for ribonucleotide binding research.
Frequently Asked Questions About ribonucleotide binding
What is ribonucleotide binding?
Ribonucleotide binding (GO:0032553) is the molecular function of selectively interacting with ribonucleotides, which are compounds consisting of a ribonucleoside esterified with phosphate or oligophosphate at any ribose hydroxyl group.
What genes are involved in ribonucleotide binding?
Genes such as RRM1, RRM2, PRKAA1, PRKAA2, PRKAG1, and PURK encode proteins that bind ribonucleotides and play roles in nucleotide metabolism, energy sensing, and biosynthesis [1,2,4,7].
How is ribonucleotide binding regulated?
It is regulated by allosteric effectors (e.g., ATP, dATP), post-translational modifications, and protein-protein interactions, as seen in ribonucleotide reductase and AMPK [1,4,5].
What diseases are associated with ribonucleotide binding?
Cancer, metabolic disorders like diabetes, and cartilage-related diseases have been linked to dysregulated ribonucleotide binding [1,2,3,5].
What methods are used to study ribonucleotide binding?
Common methods include ITC, SPR, X-ray crystallography, CRISPR screens, metabolomics, and RNA-seq [4,7,8].
Can CRISPR be used to study ribonucleotide binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes encoding ribonucleotide-binding proteins.
What is the role of AMPK in ribonucleotide binding?
AMPK binds AMP and ATP to sense energy status and regulate metabolism; mutations in its nucleotide-binding domains affect its activity [1,5].
How does ribonucleotide reductase bind substrates?
Ribonucleotide reductase binds substrates and allosteric effectors at distinct sites; binding of ATP or dATP modulates substrate specificity and activity [4,8].
What is the evolutionary significance of ribonucleotide binding?
Ribonucleotide recognition motifs are ancient, possibly originating through ligand mimicry on early Earth.
What services does EDITGENE offer for ribonucleotide binding research?
EDITGENE provides knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services for genes related to ribonucleotide binding.
Conclusion
Ribonucleotide binding (GO:0032553) is a fundamental molecular function with broad implications for cellular metabolism, nucleic acid synthesis, and signaling. Key proteins such as ribonucleotide reductase and AMPK rely on precise nucleotide binding for their activities, and their dysregulation contributes to cancer, metabolic diseases, and other pathologies. Advances in CRISPR-based models and biochemical assays continue to unravel the complexities of ribonucleotide binding, offering new avenues for therapeutic intervention. EDITGENE's comprehensive services empower researchers to dissect these mechanisms with precision.
References
- 1. Zhou G et al.. 2001. Role of AMP-activated protein kinase in mechanism of metformin action.. J Clin Invest 108(8):1167-74 PMID: 11602624
- 2. Fontecave M. 1998. Ribonucleotide reductases and radical reactions.. Cell Mol Life Sci 54(7):684-95 PMID: 9711234
- 3. Tangnijkul Y et al.. 1989. Cartilage-derived ribonucleotide binding activity.. Clin Exp Rheumatol 7(1):19-25 PMID: 2706817
- 4. Eriksson M et al.. 1997. Binding of allosteric effectors to ribonucleotide reductase protein R1: reduction of active-site cysteines promotes substrate binding.. Structure 5(8):1077-92 PMID: 9309223
- 5. Wisessaowapak C et al.. 2026. A nutrient-responsive AMPK/TBK1 circuit restricts adipocyte catabolism.. JCI Insight 11(9) PMID: 42100877
- 6. Mozumdar D et al.. 2024. Origin of ribonucleotide recognition motifs through ligand mimicry at early earth.. RNA Biol 21(1):107-121 PMID: 39526332
- 7. Tuntland ML et al.. 2014. Elucidation of the bicarbonate binding site and insights into the carboxylation mechanism of (N(5))-carboxyaminoimidazole ribonucleotide synthase (PurK) from Bacillus anthracis.. Acta Crystallogr D Biol Crystallogr 70(Pt 11):3057-65 PMID: 25372694
- 8. von Döbeln U et al.. 1976. Binding of substrates to Escherichia coli ribonucleotide reductase.. J Biol Chem 251(12):3616-22 PMID: 776972
